ALZN
Alzamend Neuro IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$4.30M
P/E Ratio
—
EPS
$-3.67
Beta
0.11
52W High
$8.22
52W Low
$0.84
50-Day MA
$1.21
200-Day MA
$1.98
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Alzamend Neuro Inc
Alzamend Neuro Inc. is an innovative biotechnology company dedicated to creating transformative therapies for neurodegenerative diseases, particularly Alzheimer's disease. Leveraging a proprietary drug development platform and a strong intellectual property portfolio, Alzamend aims to address substantial unmet medical needs in the pharmaceutical landscape. The company's commitment to advancing its therapeutic candidates through clinical trials, in combination with strategic partnerships, positions it favorably to enhance patient quality of life. With its focused efforts on critical neurological health challenges, Alzamend Neuro is set to make significant contributions to the neurotherapeutics arena.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-6.94M |
| Operating Margin | 0.00% |
| Return on Equity | -250.00% |
| Return on Assets | -107.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.57 |
| Price-to-Book | 1.97 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.13 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $3.80M |
| Float | $3.79M |
| % Insiders | 0.53% |
| % Institutions | 3.04% |
Historical Volatility
HV 10-Day
96.31%
HV 20-Day
77.36%
HV 30-Day
84.88%
HV 60-Day
116.58%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($25.00 target)
1
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026